A phase I clinical trial conducted by Emory University in collaboration with researchers from the Georgia Institute of Technology has found that influenza vaccination using Band-Aid-like patches with dissolvable microneedles was safe and well-tolerated by study participants, was just as effective in generating immunity against influenza, and was strongly preferred by study participants over vaccination with a hypodermic needle and syringe.
A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce robust immune responses and be administered safely with an experimental patch of dissolving microneedles. The method is an alternative to needle-and-syringe immunization; with further development, it could eliminate the discomfort of an injection as well as the inconvenience and expense of visiting a flu clinic.
'A single phrase can conjure up completely different images in our minds, depending on how that concept is organized in our mental models,' said Samarth Swarup, a research assistant professor at Virginia Tech.
Their study suggests that while emergency room visits for shingles has decreased for those vaccinated against either the chicken pox (18 to 19 years old) or the shingles (60 years and older), the patient population in-between (ages 20-59 years old) has experienced increased visits for the disease.
A new study has shown that boosting RV144 volunteers 6-8 years later with AIDSVAX B/E HIV vaccine resulted in higher immune responses than were seen immediately after RV144.
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching closer. Their latest study, published in the current issue of Immunity, demonstrates that optimizing the mode and timing of vaccine delivery is crucial to inducing a protective immune response in a preclinical model.
As the HIV/AIDS epidemic approaches its fourth decade, each year brings promising news of pioneering research to alleviate the scourge. Add City College of New York scientists to the list with a rapid method to access new molecules that could inhibit the virus that causes AIDS.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK funded study* published today (Monday) in Nature Immunotherapy.
A vaccine to immunise people against high levels of cholesterol and the narrowing of the arteries caused by build-up of fatty material (atherosclerosis) may be possible following successful results in mice. Now, a phase I trial in patients has started to see if the findings translate to humans. The study is published in the European Heart Journal.
A phase 1 randomized controlled trial has found an Ebola virus disease vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants six months after immunization. The study, led by Canadian researchers, is published in Canadian Medical Association Journal.